Fig. 1: Distribution and co-expression patterns of DLL3, CEACAM5, PSMA, and TROP2 expressions across different molecular subtypes of mCRPC. | npj Precision Oncology

Fig. 1: Distribution and co-expression patterns of DLL3, CEACAM5, PSMA, and TROP2 expressions across different molecular subtypes of mCRPC.

From: Assessment of TROP2, CEACAM5 and DLL3 in metastatic prostate cancer: Expression landscape and molecular correlates

Fig. 1: Distribution and co-expression patterns of DLL3, CEACAM5, PSMA, and TROP2 expressions across different molecular subtypes of mCRPC.The alternative text for this image may have been generated using AI.

a Representative images of cell surface antigen expression (determined by IHC) across different molecular subtypes (AR + /NE- [green], AR-/NE+ [yellow], AR + /NE+ [red], and AR-/NE- [blue]). Molecular subtypes were defined by expression of AR signaling markers (AR, NKX3.1) and NE markers (SYP, INSM1) as described previously20. Box plots show the distribution of (b) DLL3, (c). CEACAM5, and d. TROP2 expressions based on H-score in the UW-TAN cohort (N = 753). Box and dot colors indicate molecular phenotypes as above. e Top, micrographs of PSMA and TROP2 in AR + /NE- tumors. Bottom, donut chart shows the distribution of PSMA and TROP2 reactivity. f Top, micrographs of DLL3 and CEACAM5 in AR-/NE+ tumors. Bottom, donut chart shows the distribution of DLL3 and CEACAM5 reactivity. (See Supplementary Table 2 for all co-expression profiles). Scale bars denote 50 μm.

Back to article page